Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784745 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4283706 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL12026599 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL1477254 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL971919 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| SCHEMBL29744950 | 1.00 | OPRM1 (0.57) | OPRM1OPRK1OPRD1 | |
| Phenol SCHEMBL9660770 | 0.96 | OPRM1 (0.53) | OPRM1OPRK1OPRD1 | |
| Phenol SCHEMBL9660778 | 0.96 | OPRM1 (0.53) | OPRM1OPRK1OPRD1 | |
| SCHEMBL1019742 | 0.81 | OPRM1 (0.46) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5137090 | 0.81 | OPRM1 (0.46) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259818-A1 | Methods and Compositions for Treating Conditions | NEOPRO LABS, LLC | 2007-11-08 | — | — | US | claimed |
| CN-109790125-B | Tetrahydroisoquinoline kappa opioid antagonists | 研究三角协会 | 2022-07-05 | — | — | CN | disclosed |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| US-10377698-B2 | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production | UNIVERSITY OF INNSBRUCK (AT) | 2019-08-13 | — | — | US | disclosed |
| EP-3512832-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | Research Triangle Institute, International (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072654-A1 | Diphenethylamine Derivatives Which Are Inter Alia Useful As Analgesics And Method For Their Production | Spetea, Mariana, Dr. (AT) | 2018-03-15 | — | — | US | disclosed |
| EP-3277659-A1 | DIPHENETHYLAMINE DERIVATIVES WHICH ARE INTER ALIA USEFUL AS ANALGESICS AND METHODS FOR THEIR PRODUCTION | University of Innsbruck (AT) | 2018-02-07 | — | — | EP | disclosed |
| EP-0506468-A1 | N-substituted 4-phenyl-piperidine opioid-antagonists | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506478-A1 | Piperidine derivatives | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5064834-A | That block mu or kappa receptors in the brain | ELI LILLY AND COMPANY (US) | 1991-11-12 | — | — | US | disclosed |
| US-4992450-A | Piperidine opioid antagonists | ELI LILLY AND COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| US-4891379-A | BLOCKING MU OR KAPPA RECEPTORS | KABUSHIKI KAISHA KOBE SEIKOSHO (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0287339-A2 | Piperidine opioid antagonists | ELI LILLY AND COMPANY (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4191771-A | NARCOTIC ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1980-03-04 | — | — | US | disclosed |
| US-4175197-A | 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4115400-A | 1-Azoniabicyclo[3.1.0]hexanes | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081450-A | 1,3,4-Trisubstituted-4-arylpiperidines and their preparation | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072654-A1 | Diphenethylamine Derivatives Which Are Inter Alia Useful As Analgesics And Method For Their Production | PNMT, OPRL1, OPRK1 | OPRM1 21/4885OPRK1 3/4885OPRD1 4/4885 |
| US-10377698-B2 | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production | PNMT, OPRL1, OPRK1 | OPRM1 18/4885OPRK1 3/4885OPRD1 4/4885 |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.